Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Article Type
- Review1
- Research Support, U.S. Gov't, Non-P.H.S.1
- Research Support, U.S. Gov't, P.H.S.1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Med Clin North Am1
Search Results
Sort by
- BookFlavia Fontana, Hélder A. Santos, editors.Summary: The book covers the latest developments in biologically-inspired and derived nanomedicine for cancer therapy. The purpose of the book is to illustrate the significance of naturally-mimicking systems for enhancing the dose delivered to the tumor, to improve stability, and prolong the circulation time. Moreover, readers are presented with advanced materials such as adjuvants for immunostimulation in cancer vaccines. The book also provides a comprehensive overview of the current status of academic research. This is an ideal book for students, researchers, and professors working in nanotechnology, cancer, targeted drug delivery, controlled drug release, materials science, and biomaterials as well as companies developing cancer immunotherapy.
Contents:
Part 1
Conventional nanosized drug delivery systems for cancer applications
Homing peptides for cancer therapy
Radiolabeling of theranostic nanosystems
Boosting nanomedicine efficacy with hyperbaric oxygen therapy
Part 2
Mesoporous Silica Nanoparticles as Carriers for Biomolecules in Cancer Therapy
Clearable Nanoparticles for Cancer Photothermal Therapy
Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds
Electrospun Nanofibers for Cancer Therapy
Nanoneedle-based materials for intracellular studies
Part 3
In vitro assays for nanoparticle-cancer cell interaction studies
3D tumor spheroid models for in vitro therapeutic screening of nanoparticles
In vitro and in vivo tumor models for the evaluation of anticancer nanoparticles
Part 4
Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy
Viral nanoparticles: cancer vaccines and immune modulators
Industrial Perspective on Cancer Immunotherapy
Index. - ArticleRaskin P, Unger RH.Med Clin North Am. 1978 Jul;62(4):713-22.We have considered the evidence, first, that the presence of glucagon is essential in the pathogenesis of the full syndrome that results from complete insulin deficiency; second, that in the diabetic in whom insulin levels are relatively fixed, a rise in glucagon concentration contributes to endogenous hyperglycemia; and, third, that conventional methods of treatment of diabetes do not fully correct either the abnormal glucagon levels or the hyperglycemia, but when insulin therapy is supplemented with somatostatin, an agent which suppresses both glucagon and growth hormone, both hyperglycemia and hyperglucagonemia are corrected. These facts may one day provide a rationale for therapeutic efforts to suppress excess glucagon secretion in the management of diabetes in man.